Phase 2 Brain Cancer Trial, Recruiting NCT04765098 Sponsor: AHS Cancer Control Alberta Condition: Brain Cancer
Back to Brain Cancer

Phase 2 Brain Cancer Trial, Recruiting

NCT04765098
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with glioblastoma (a type of brain tumour), confirmed by laboratory testing of tumour tissue, whose cancer has come back or grown after completing standard first-line treatment (chemotherapy with temozolomide combined with radiotherapy).
  • People whose cancer progression has been confirmed by an MRI scan, showing at least one measurable tumour area of a specific minimum size visible across multiple scan images.
  • People who have not received radiotherapy within the three months before their cancer was confirmed to have progressed.
  • People whose steroid medication (dexamethasone) dose has been stable or decreasing before joining the trial, and is being kept at the lowest dose needed to manage symptoms.
  • People with a general health and activity level rated at 0–2 on a standard medical scale (meaning they are fully active to capable of limited self-care) (confirm with trial site).
  • People aged 18 to 65 years.
  • Women who could become pregnant must have a negative pregnancy test (blood or urine) within 72 hours before the first treatment dose.
  • People who are able to have children must use reliable contraception during treatment and for 60 days after the last dose.
  • People with blood test results within an acceptable range, taken within 7 days before joining, showing the blood, kidney, and liver are functioning adequately.
  • People who are able to understand the trial and provide signed consent before registering.

Who may not be able to join:

  • People who currently have, or have had in the past, another type of cancer — unless they have been cancer-free for at least 3 years, or had a completely removed non-melanoma skin cancer, or a successfully treated early-stage cancer such as cervical cancer in situ.
  • People with uncontrolled high blood pressure (readings above 150/100 mmHg).
  • People who have had a blood clot in an artery or vein within the 6 months before registering.
  • People whose brain MRI shows signs of recent bleeding in the brain.
  • People with serious heart or blood vessel conditions, including a stroke within the past 6 months, a heart attack within the past 6 months, unstable chest pain, significant heart failure, or a serious heart rhythm problem requiring medication.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 780-432-8290

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
AHS Cancer Control Alberta
Registry
ClinicalTrials.gov
Start date
28 January 2022
Est. completion
1 December 2026

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

3 month progression-free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov